NorthWest Biotherapeutics Inc (NWBO)

[underpar71]

Not a good one.....this is what this Dr. concluded:

"However, there are many significant concerns about the post hoc re-analysis of the data that call into question the validity of the conclusions. A major concern is the lack of patient-level data in the external control group, reducing the utility of that control. There are also other sources of bias, such as the exclusion of patients with rapidly growing tumors from enrolling in the trial and the likely selection of patients with a good prognosis in the control group for the administration of the vaccine. As a result of these and other concerns, the therapeutic value of this vaccine remains unclear."